Association of lymphocyte subsets with the efficacy and prognosis of PD‑1 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study

Table 1 Clinical and pathological characteristics

Characteristics	N	%
Age
<65	117	60.00
≥ 65	78	40.00
Gender
Female	54	27.69
Male	141	72.31
BMI
BMI<18.5 kg/m2	35	17.95
BMI ≥ 18.5 kg/m2	160	82.05
Smoking history
No	106	54.36
Yes	89	45.64
Drinking history
No	141	72.31
Yes	54	27.69
Extensive metastasis
No	78	40.00
Yes	117	60.00
PD-L1 expression
CPS<5	105	53.85
CPS ≥ 5	90	46.15
Mismatch repair status
pMMR	186	95.38
dMMR	9	4.62
Treatment line
First line	53	27.18
Second line and beyond	142	72.82
Treatment model
ICIs alone	12	6.15
Chemotherapy combined with ICIs	173	88.72
Anti-angiogenesis drugs combined with ICIs	10	5.13
Tumor response
Complete response	2	1.03
Partial response	53	27.18
Stable disease	89	45.64
Progressive disease	51	26.15

ISSN: 1471-230X